Price movement over the last 24 hours
ARK Genomic Revolution ETF vs Intuitive Surgical, Inc. — how do they compare? ARK Genomic Revolution ETF trades at $41.25, while Intuitive Surgical, Inc. trades at $409.62 (market cap $144.07B). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, Intuitive Surgical, Inc. nearer its low. Which is the better fit depends on your goals.
| ARKG | ISRG | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $43.57 | $592.85 |
52-Week Low | $23.09 | $397.68 |
Market Cap | — | $144.07B |
Enterprise Value | — | $139.55B |
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Intuitive Surgical (ISRG) trades at $406.78, down 1.16% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q1 2026 earnings of $2.50 EPS, beating estimates, with revenue reaching $10.06 billion in 2025 and net income margin at 28.15%. Analyst consensus is bullish with a $556.10 price target, though valuation ratios like P/E of 49.43 remain elevated. Recent news highlights Q2 2026 earnings anticipation on July 16 and ongoing adoption of da Vinci 5 systems.
Outlook is positive due to consistent earnings beats and robust revenue growth, but risks include high valuation sensitivity and competitive pressures. The stock offers long-term growth potential in robotic surgery, yet investors should monitor margin trends and quarterly results for sustained momentum amid market volatility.
Trailing returns across standard periods
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →